Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36742
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLu M.en
dc.contributor.authorDavies D.en
dc.contributor.authorDavies J.en
dc.contributor.authorChan S.en
dc.contributor.authorBarnacle B.en
dc.contributor.authorLee A.en
dc.contributor.authorKovitwanichkanont T.en
dc.date.accessioned2021-05-14T12:28:06Zen
dc.date.available2021-05-14T12:28:06Zen
dc.date.copyright2019en
dc.date.created20190605en
dc.date.issued2019-06-05en
dc.identifier.citationAustralasian Journal of Dermatology. Conference: 52nd Annual Scientific Meeting of the Australasian College of Dermatologists. Melbourne, VIC Australia. 60 (Supplement 1) (pp 54-55), 2019. Date of Publication: May 2019.en
dc.identifier.issn1440-0960en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36742en
dc.description.abstractBackground: Strip patch testing is 30 times more sensitive compared to traditional patch testing as it reduces the stratum corneum thickness by 50% thereby allowing a 30% reduction of standard test substance concentration. Positive patch test results accomplished at lower concentrations improve the validity of allergenicity of test substances. Our objective was to formulate lower concentration test substances and to compare sensitivity of strip versus traditional patch testing at lower concentrations. Case Description: A 33 year-old Asian woman was admitted with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome after two days of tuberculosis (TB) therapy consisting of rifampicin, isoniazid, ethambutol, pyrazinamide and pyridoxine. Patch testing was used to identify causative medication(s) to guide secondline treatment options. A previous case study tested all five TB medications using white soft paraffin (WSP); however, negative reactions were observed at lower concentrations. For our case, ethambutol 1%, pyrazinamide 1% and pyridoxine 10% was formulated in WSP as they are poorly water-soluble; however, isoniazid is highly water-soluble therefore a 1% aqueous solution was formulated for better skin penetration. The formulated test substances and intravenous rifampicin solution were used for both strip and traditional patch testing. Using the standard reading criteria, positive reactions occurred with all five TB medications via strip patch testing whereas traditional patch testing only showed positive reactions for rifampicin, isoniazid and ethambutol. Conclusion(s): Our department successfully formulated lower concentrations of test substances for strip patch testing which was found to be more sensitive than traditional patch testing.en
dc.languageenen
dc.languageEnglishen
dc.publisherBlackwell Publishingen
dc.titleStrip versus traditional patch testing enhanced percutaneous penetration of anti-tuberculosis test substances at lower concentrations.en
dc.typeConference Abstracten
dc.identifier.affiliationPharmacyen
dc.identifier.affiliationDermatologyen
dc.identifier.affiliationInfectious Diseasesen
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/ajd.13027en
local.date.conferencestart2019-05-18en
dc.identifier.source627912140en
dc.identifier.institution(Lu, Davies, Davies, Chan) Pharmacy Department, Monash Health, Melbourne, VIC, Australia (Barnacle, Lee, Kovitwanichkanont) Department of Dermatology, Monash Health, Melbourne, VIC, Australia (Kovitwanichkanont) Department of Infectious Diseases, Monash Health, Melbourne, VIC, Australiaen
dc.description.addressM. Lu, Pharmacy Department, Monash Health, Melbourne, VIC, Australiaen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2019-05-21en
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.identifier.affiliationmh(Lu, Davies, Davies, Chan) Pharmacy Department, Monash Health, Melbourne, VIC, Australia-
dc.identifier.affiliationmh(Barnacle, Lee, Kovitwanichkanont) Department of Dermatology, Monash Health, Melbourne, VIC, Australia-
dc.identifier.affiliationmh(Kovitwanichkanont) Department of Infectious Diseases, Monash Health, Melbourne, VIC, Australia-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeConference Abstract-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Conferences
Show simple item record

Page view(s)

18
checked on Sep 29, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.